Extracellular Vesicle Molecular Signatures Characterize Metastatic Dynamicity in Ovarian Cancer.

exosome extracellular vesicle gene signatures metastasis ovarian cancer 2

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2021
Historique:
received: 31 05 2021
accepted: 29 10 2021
entrez: 6 12 2021
pubmed: 7 12 2021
medline: 7 12 2021
Statut: epublish

Résumé

Late-stage diagnosis of ovarian cancer, a disease that originates in the ovaries and spreads to the peritoneal cavity, lowers 5-year survival rate from 90% to 30%. Early screening tools that can: i) detect with high specificity and sensitivity before conventional tools such as transvaginal ultrasound and CA-125, ii) use non-invasive sampling methods and iii) longitudinally significantly increase survival rates in ovarian cancer are needed. Studies that employ blood-based screening tools using circulating tumor-cells, -DNA, and most recently tumor-derived small extracellular vesicles (sEVs) have shown promise in non-invasive detection of cancer before standard of care. Our findings in this study show the promise of a sEV-derived signature as a non-invasive longitudinal screening tool in ovarian cancer. Human serum samples as well as plasma and ascites from a mouse model of ovarian cancer were collected at various disease stages. Small extracellular vesicles (sEVs) were extracted using a commercially available kit. RNA was isolated from lysed sEVs, and quantitative RT-PCR was performed to identify specific metastatic gene expression. This paper highlights the potential of sEVs in monitoring ovarian cancer progression and metastatic development. We identified a 7-gene panel in sEVs derived from plasma, serum, and ascites that overlapped with an established metastatic ovarian carcinoma signature. We found the 7-gene panel to be differentially expressed with tumor development and metastatic spread in a mouse model of ovarian cancer. The most notable finding was a significant change in the ascites-derived sEV gene signature that overlapped with that of the plasma-derived sEV signature at varying stages of disease progression. While there were quantifiable changes in genes from the 7-gene panel in serum-derived sEVs from ovarian cancer patients, we were unable to establish a definitive signature due to low sample number. Taken together our findings show that differential expression of metastatic genes derived from circulating sEVs present a minimally invasive screening tool for ovarian cancer detection and longitudinal monitoring of molecular changes associated with progression and metastatic spread.

Sections du résumé

BACKGROUND BACKGROUND
Late-stage diagnosis of ovarian cancer, a disease that originates in the ovaries and spreads to the peritoneal cavity, lowers 5-year survival rate from 90% to 30%. Early screening tools that can: i) detect with high specificity and sensitivity before conventional tools such as transvaginal ultrasound and CA-125, ii) use non-invasive sampling methods and iii) longitudinally significantly increase survival rates in ovarian cancer are needed. Studies that employ blood-based screening tools using circulating tumor-cells, -DNA, and most recently tumor-derived small extracellular vesicles (sEVs) have shown promise in non-invasive detection of cancer before standard of care. Our findings in this study show the promise of a sEV-derived signature as a non-invasive longitudinal screening tool in ovarian cancer.
METHODS METHODS
Human serum samples as well as plasma and ascites from a mouse model of ovarian cancer were collected at various disease stages. Small extracellular vesicles (sEVs) were extracted using a commercially available kit. RNA was isolated from lysed sEVs, and quantitative RT-PCR was performed to identify specific metastatic gene expression.
CONCLUSION CONCLUSIONS
This paper highlights the potential of sEVs in monitoring ovarian cancer progression and metastatic development. We identified a 7-gene panel in sEVs derived from plasma, serum, and ascites that overlapped with an established metastatic ovarian carcinoma signature. We found the 7-gene panel to be differentially expressed with tumor development and metastatic spread in a mouse model of ovarian cancer. The most notable finding was a significant change in the ascites-derived sEV gene signature that overlapped with that of the plasma-derived sEV signature at varying stages of disease progression. While there were quantifiable changes in genes from the 7-gene panel in serum-derived sEVs from ovarian cancer patients, we were unable to establish a definitive signature due to low sample number. Taken together our findings show that differential expression of metastatic genes derived from circulating sEVs present a minimally invasive screening tool for ovarian cancer detection and longitudinal monitoring of molecular changes associated with progression and metastatic spread.

Identifiants

pubmed: 34868914
doi: 10.3389/fonc.2021.718408
pmc: PMC8637407
doi:

Types de publication

Journal Article

Langues

eng

Pagination

718408

Subventions

Organisme : NIBIB NIH HHS
ID : R01 EB018378
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM135141
Pays : United States

Informations de copyright

Copyright © 2021 Gonda, Zhao, Shah, Siebert, Gunda, Inan, Kwon, Libutti, Moghe, Francis and Ganapathy.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Trends Pharmacol Sci. 2019 Mar;40(3):172-186
pubmed: 30736982
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
Elife. 2020 Oct 07;9:
pubmed: 33026975
J Cell Physiol. 2021 Oct;236(10):6907-6919
pubmed: 33655494
Cancer Res. 2019 May 1;79(9):2271-2284
pubmed: 30862717
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Cancers (Basel). 2020 Jan 27;12(2):
pubmed: 32012717
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
JAMA. 2018 Feb 13;319(6):595-606
pubmed: 29450530
Front Oncol. 2020 Apr 15;10:397
pubmed: 32351878
Exp Biol Med (Maywood). 2018 Feb;243(3):262-271
pubmed: 29405770
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):607-614
pubmed: 32382078
Drug Resist Updat. 2019 Dec;47:100647
pubmed: 31704541
Br J Nurs. 2013 Sep 12-25;22(17):S23-30
pubmed: 24067270
Am Fam Physician. 2016 Jun 1;93(11):937-44
pubmed: 27281838
Mol Cancer. 2014 Oct 24;13:241
pubmed: 25344116
Biostat Bioinforma Biomath. 2013 Aug;3(3):71-85
pubmed: 25558171
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
Oncol Rep. 2020 Oct;44(4):1671-1685
pubmed: 32945508
Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794630
pubmed: 30181785
Gynecol Oncol. 2021 Feb;160(2):530-538
pubmed: 33317907
Expert Rev Mol Diagn. 2020 Apr;20(4):387-400
pubmed: 32067543
J Oncol. 2020 May 27;2020:8097872
pubmed: 32565808
Ultrasound Obstet Gynecol. 2018 Mar;51(3):293-303
pubmed: 28639753
Front Cardiovasc Med. 2017 Oct 09;4:63
pubmed: 29062835
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Semin Oncol Nurs. 2019 Apr;35(2):151-156
pubmed: 30867104
Bioinformatics. 2014 Aug 15;30(16):2310-6
pubmed: 24764462
Oncol Rep. 2012 May;27(5):1587-91
pubmed: 22344746
Hepatogastroenterology. 2013 May;60(123):620-3
pubmed: 23635433
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Br J Radiol. 2018 Oct;91(1090):20170571
pubmed: 30102555
Ann Oncol. 2021 Apr;32(4):466-477
pubmed: 33548389
Oncol Lett. 2017 Oct;14(4):3967-3974
pubmed: 28943904
Cancers (Basel). 2019 Mar 26;11(3):
pubmed: 30917536
Clin Transl Sci. 2019 Sep;12(5):431-439
pubmed: 31162800
J Ovarian Res. 2019 Mar 27;12(1):28
pubmed: 30917847
Oncogene. 2014 Jun 26;33(26):3432-40
pubmed: 23934190
Dan Med J. 2018 Apr;65(4):
pubmed: 29619933
Cancer Cell. 2003 Apr;3(4):377-86
pubmed: 12726863
Cell Cycle. 2014;13(15):2319
pubmed: 25483179
Clin Lab. 2019 May 1;65(5):
pubmed: 31115211
Sci Rep. 2017 Aug 29;7(1):9689
pubmed: 28851888
PLoS One. 2014 Apr 14;9(4):e94476
pubmed: 24732363
Oncologist. 2020 Mar;25(3):235-243
pubmed: 32162812
Clin Cancer Res. 2014 Feb 1;20(3):711-23
pubmed: 24218511
Nature. 2020 Mar;579(7800):S10-S11
pubmed: 32214255
Obstet Gynecol. 2018 May;131(5):909-927
pubmed: 29630008
Cancers (Basel). 2020 May 28;12(6):
pubmed: 32481580
Am J Clin Pathol. 2010 Nov;134(5):835-45
pubmed: 20959669
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Oncotarget. 2017 Jul 11;8(48):84546-84558
pubmed: 29137447
Oncotarget. 2017 Jun 27;8(26):42983-42996
pubmed: 28562334
Lung Cancer. 2019 Aug;134:96-99
pubmed: 31320002
J Ovarian Res. 2019 Nov 26;12(1):116
pubmed: 31771659
Ann Lab Med. 2018 Jan;38(1):1-8
pubmed: 29071812
Urol Oncol. 2015 Sep;33(9):385.e15-20
pubmed: 26027763
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322519
Front Immunol. 2018 Apr 30;9:738
pubmed: 29760691
Cancers (Basel). 2019 May 20;11(5):
pubmed: 31137558
Nat Commun. 2020 Jul 21;11(1):3475
pubmed: 32694610
Am Soc Clin Oncol Educ Book. 2018 May 23;38:978-997
pubmed: 30231331
Oncotarget. 2017 Feb 7;8(6):9717-9738
pubmed: 28038455
Front Oncol. 2015 Nov 02;5:245
pubmed: 26579497
PLoS One. 2015 Mar 25;10(3):e0120107
pubmed: 25807548
Cancer Metastasis Rev. 2020 Dec;39(4):1223-1243
pubmed: 32780245
Breast Cancer Res. 2016 Sep 08;18(1):90
pubmed: 27608715
PLoS One. 2017 Mar 23;12(3):e0173709
pubmed: 28333953
Clin Chim Acta. 2013 Feb 18;417:39-44
pubmed: 23266771
Gastroenterol Res Pract. 2012;2012:541842
pubmed: 22888339
PLoS One. 2017 Jan 23;12(1):e0170628
pubmed: 28114422

Auteurs

Amber Gonda (A)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, United States.

Nanxia Zhao (N)

Department of Chemical and Biochemical Engineering, Rutgers University, Piscataway, NJ, United States.

Jay V Shah (JV)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, United States.

Jake N Siebert (JN)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, United States.
Rutgers-Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, United States.

Srujanesh Gunda (S)

School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ, United States.

Berk Inan (B)

School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ, United States.

Mijung Kwon (M)

Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, United States.

Steven K Libutti (SK)

Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, United States.

Prabhas V Moghe (PV)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, United States.
Department of Chemical and Biochemical Engineering, Rutgers University, Piscataway, NJ, United States.

Nicola L Francis (NL)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, United States.

Vidya Ganapathy (V)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, United States.

Classifications MeSH